City

Beijing (2)

Condition

Chronic Hepatics C Virus (HCV) Genotype 1 (2)

Cirrhosis (2)

Non-Cirrhotic (2)

Treatment naive (2)

Overall Status

Completed (2)

Sign in for free

Phase

phase 2 (1)

phase 3 (1)

Sponsor

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. (2)

Collaborator

Peking University People's Hospital (1)

Intervention

cirrhotic subjects. high tg-2349+ high dag181 (1)

cirrhotic subjects. high tg-2349+ high dag181+ribavirin (1)

dag181 (1)

non-cirrhotic subjects. high tg-2349+ high dag181 (1)

non-cirrhotic subjects. high tg-2349+ high dag181+ribavirin (1)

non-cirrhotic subjects. low tg-2349+ low dag181 (1)

non-cirrhotic subjects. low tg-2349+ low dag181+ribavirin (1)

ribavirin (1)

tg-2349 (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

Study Type

Interventional (2)

chronic hepatics c virus (hcv) genotype 1

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis Trial in Beijing (non-cirrhotic subjects. low TG-2349+ low

Completed

Chronic Hepatics C Virus (HCV) Genotype 1
+3 more

non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin
+5 more

Beijing, Beijing, China

Peking University Peoples Hospital

Feb 16, 2021

Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis Trial in Beijing (TG-2349, DAG181, Ribavirin)

Completed

Chronic Hepatics C Virus (HCV) Genotype 1
+3 more

TG-2349
+2 more

Beijing, China

Beijing Tsinghua Changgung Hospital

Feb 2, 2021